PRTCY (PureTech Health) Moat Score: 6/10 (As of Jun. 24, 2026)


PRTCY PureTech Health PLC PRTCY
62 GF Score
Price $17.54
GF Value $70.09
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is PureTech Health Moat Score?

PureTech Health PRTCY +1.49% 62 Moat Score is 6 as of Jun. 24, 2026. GuruFocus rates PRTCY with a GF Score™ of 62/100 and a GF Value™ of $70.09 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,405 Biotechnology companies, PureTech Health ranks better than 98.93% on this metric.

PureTech Health has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

PureTech Health has Narrow Moat: PureTech Health PLC has strong R&D capabilities and valuable intellectual property. The company benefits from innovation and some regulatory barriers, providing a strong narrow moat, though not wide due to limited market share.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes PureTech Health might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

PureTech Health  (OTCPK:PRTCY) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

PureTech Health Moat Score Related Terms

PRTCY vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, PureTech Health's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PureTech Health Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PureTech Health's Moat Score distribution charts can be found below:

* The bar in red indicates where PureTech Health's Moat Score falls into.


PRTCY
62GF Score
PureTech Health PLC PRTCY
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
PureTech Health (PRTCY) has a Moat Score of 6 as of Jun. 24, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, PureTech Health ranks #15 out of 1405 companies in the Biotechnology industry, placing it in the top 1.1%.
Is PureTech Health's Moat Score too high?
PureTech Health's current Moat Score is 6. The Biotechnology industry median Moat Score is 2.00. PureTech Health's value of 6 is 200% above this industry median. Based on the distribution chart, PureTech Health ranks #15 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PureTech Health has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PureTech Health ranks #15 out of 1405 companies for Moat Score. This places PureTech Health in the top 1% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. PureTech Health's value of 6 is 200% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PureTech Health's current Moat Score of 6 is 200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PureTech Health's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (PRTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $70.09, compared to a current price of $17.54 — trading 75% below its estimated fair value. The current Moat Score is 6 and 200% above the Biotechnology industry median of 2.00. PureTech Health's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For PureTech Health (PRTCY), the current Moat Score is 6 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PureTech Health (PRTCY) Overvalued in 2026?

Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued. The current stock price of $17.54 is trading 75% below its estimated GF Value™ of $70.09. GuruFocus considers PureTech Health to be Possible Value Trap.

Key valuation signals for PRTCY:

  • Moat Score: 6
  • GF Value™: $70.09 vs. price of $17.54 (75% below fair value)
  • GF Score™: 62/100 with 4 warning signs
  • Industry Position: 200% above the Biotechnology median (#15 of 1405)

No single metric tells the full story. See the PRTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PureTech Health Business Description

Address 6 Tide Street, Suite 400, Boston, MA, USA, 02210
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
62GF Score

Get the complete analysis for PRTCY

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.54
Price
$70.09
GF Value